(Updated to include analyst commentary)
Truist Securities raised Jazz Pharmaceuticals price target to $230 from $220 following the company's decision to acquire Chimerix in an all-cash deal worth $935 million, or $8.55 per share.
In a March 5 report, the brokerage wrote that it sees the acquisition as "exciting" and noted that dordaviprone could be accretive near term. The drug received priority review in August for a rare form of high-grade glioma (H3 K27M+), "with a potential approval on the horizon."
With the acquisition, Jazz will also gain access to ONC206, a next-generation, more potent compound targeting ClpP/DRD2. In addition, the brokerage mentioned that the company may be eligible for Rare Pediatric Disease Priority Review Voucher, upon approval of dordaviprone, which can be monetized.
Jazz Pharmaceuticals (JAZZ) has an average rating of buy and mean price target of $190.69, according to analysts polled by FactSet.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Price: 136.77, Change: -3.46, Percent Change: -2.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。